SMS Pharmaceuticals profit and loss

Latest FY26

Revenue: ₹887cr+13.3% on FY25
EBITDA: ₹171cr+23.2% on FY25
Net profit: ₹102cr+47.5% on FY25
EPS: ₹11.15+36.6% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	898	887	783	709	522	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	9.5	8.4	6.2	4.5	4.9
	907	895	789	714	527
	511	516	502	425	300
	−11.5	−23.1	−64.8	−1.0	36.1
	93.3	88.0	80.1	64.1	55.0
	22.7	23.1	18.5	23.5	21.9
	40.2	39.9	34.3	31.5	32.1
	132	134	127	104	76.7
	788	779	697	648	522
	173	171	139	117	54.5
	133	131	105	85.1	22.4
Profit
	119	117	92.3	66.1	5.3
	119	117	92.3	66.1	5.3
	27.0	25.9	19.6	15.1	−0.0
	3.0	2.7	5.3	1.8	1.5
	30.0	28.6	24.9	16.9	1.5
	12.9	14.0	1.7	0.6	−10.9
	102	102	69.1	49.8	−7.1
	89.5	88.0	67.4	49.2	3.9
	0.1	0.1	−0.5	0.1	−0.2
	103	102	68.6	49.9	−7.2
	103	102	68.6	49.8	−7.1
Per share
	₹11.24	₹11.15	₹8.16	₹5.89	−₹0.83
	₹11.24	₹11.15	₹8.16	₹5.89	₹0.00
Other comprehensive income — detail
	0.1	0.1	−0.5	—	—
	—	—	—	0.1	−0.2
	−0.1	−0.1	0.5	—	—
	103	102	68.6	49.8	−0.2
	0.0	0.0	0.0	0.0	−7.2
Per share — as-filed variants
	₹11.24	₹11.15	₹8.16	₹5.89	−₹0.83
	₹11.24	₹11.15	₹8.16	₹5.89	₹0.00
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	398	394	346	285	186
	44.4%	44.4%	44.2%	40.2%	35.7%
Adjusted (ex-exceptional items) — derived
	119	117	92.3	66.1	5.3
	102	102	69.1	49.8	−7.1
	₹11.24	₹11.15	₹8.16	₹5.89	−₹0.83

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SMSPHARMA₹475.45

SMS Pharmaceuticals Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersINDSWFTLAB SOLARA DCAL UNICHEMLAB GUFICBIO RPGLIFE HIKAL GUJTHEMMcap ₹4,453 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	522.1	709.3	782.7	886.9	897.8
Other Income	4.9	4.5	6.2	8.4	9.5
Total Income	526.9	713.7	789.0	895.2	907.3
Expenses
+ Cost of Materials Consumed	299.7	425.3	501.9	516.4	510.9
+ Changes in Inventories	36.1	-1.0	-64.8	-23.1	-11.5
+ Employee Benefit Expense	55.0	64.1	80.1	88.0	93.3
+ Finance Costs	21.9	23.5	18.5	23.1	22.7
+ Depreciation & Amortisation	32.1	31.5	34.3	39.9	40.2
+ Other Expenses	76.7	104.2	126.6	134.3	132.3
Total Expenses	521.6	647.6	696.6	778.6	787.8
EBITDA	54.5	116.6	139.0	171.3	172.9
EBIT	22.4	85.1	104.7	131.4	132.7
Profit
PBT before Exceptional Items	5.3	66.1	92.3	116.6	119.5
Pretax Income	5.3	66.1	92.3	116.6	119.5
+ Current Tax	-0.0	15.1	19.6	25.9	27.0
+ Deferred Tax	1.5	1.8	5.3	2.7	3.0
Tax Expense	1.5	16.9	24.9	28.6	30.0
+ Share of Associates & JVs	-10.9	0.6	1.7	14.0	12.9
Net Income	-7.1	49.8	69.1	102.0	102.4
+ Net Income — Continuing Ops	3.9	49.2	67.4	88.0	89.5
+ Other Comprehensive Income	-0.2	0.1	-0.5	0.1	0.1
Total Comprehensive Income	-7.2	49.9	68.6	102.1	102.5
Net Income to Common	-7.1	49.8	68.6	102.1	102.7
Per Share
Basic EPS	-0.83	5.89	8.16	11.15	11.24
Diluted EPS	0.00	5.89	8.16	11.15	11.24
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-0.5	0.1	0.1
+ Items NOT to be Reclassified to P&L	-0.2	0.1	—	—	—
+ Tax on Items NOT to be Reclassified	—	—	0.5	-0.1	-0.1
Comprehensive Income — Owners of Parent	-0.2	49.8	68.6	102.1	102.5
Comprehensive Income — Non-controlling Interests	-7.2	0.0	0.0	0.0	0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations	-0.83	5.89	8.16	11.15	11.24
Diluted EPS — Continuing Operations	0.00	5.89	8.16	11.15	11.24
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	186.2	285.0	345.7	393.5	398.5
Gross Margin %	35.67	40.18	44.16	44.37	44.38
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	5.3	66.1	92.3	116.6	119.5
Net Income Adj (tax-effected)	-7.1	49.8	69.1	102.0	102.4
EPS Adj	-0.83	5.89	8.16	11.15	11.24
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	8.5	8.5	8.9	9.4	9.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.